Bevacizumab Suppresses Choroidal Neovascularization Caused by Pathological Myopia

Abstract

Purpose: To report the successful use of intravitreal bevacizumab (Avastin) in pathologic myopic patient with choroidal neovascularization. Method: From February 2006 to March 2008, we collected 20 pathologic myopic patient with CNV. They were injected intravitreally with bevacizumab (Avastin) 1.25 mg (0.05 mL). Injection was repeated at two months interval once the intraretinal edema or subretinal fluid was detected. Result Patient received injections ranging from 1 to 5 times. Efficacy was evaluated by reduction in central foveal thickness. BCVA was also recorded during treatment period. Average reduction in absolute central foveal thickness was 19 um. BCVA improved by a means of 0.5 (logMAR). Average SRF-free period was 38.7 weeks. Conclusion: Intravitreal Bevacizumab was injected successively in cases of pathologic myopia with CNV. BCVA was improved for most patients. Reduced or resolved angiographic leakage and reduction in macular thickness was noted in all our cases.